Cencora, Inc. (COR) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Camino Minerals Corporation (COR) has commenced drilling at its Costa de Cobre IOCG copper discovery in Peru, marking a significant step in the project's exploration and development. This drilling campaign is part of a new joint venture with Nittetsu Mining, where COR will operate and hold a 65% interest. The project, formerly known as Los Chapitos, has been rebranded to emphasize its coastal location and infrastructure advantages. This development is crucial for unlocking the potential of this district-scale copper asset. Investors will be watching for initial assay results from the drilling to gauge the project's economic viability. The success of this exploration phase could significantly impact COR's future production outlook.

Market Data

COR Stock Snapshot

Cencora, Inc. · Healthcare · cencora.com

Cencora, Inc. is a global pharmaceutical distribution and services company, operating through two primary segments: U.S. and International Healthcare Solutions. The company's core business involves the sourcing and distribution of a wide array of pharmaceutical products, including generics, injectables, over-the-counter medications, and specialty pharmaceuticals, serving a diverse customer base encompassing hospitals, pharmacies, and clinics. Cencora also provides value-added services such as pharmacy management, consulting, and data analytics, supporting both healthcare providers and pharmaceutical manufacturers. With a history dating back to 1871, the company, formerly known as AmerisourceBergen Corporation, has established itself as a key player in the healthcare supply chain, offering comprehensive solutions across various healthcare sectors.

COR is currently trading at $326.50, giving Cencora, Inc. a market cap of 63.72B and a P/E ratio of 39.2. Today's range spans $318.06–$327.71, with shares opening at $322.37 and moving down $1.09 (0.3%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 56/100.

Over the past year COR has traded between $271.00 and $377.54 - the current price is +20.5% off the 52-week low and -13.5% from the high. 20 analysts cover the stock with a Buy consensus and a mean 12-month target of $402.92 (range $340.00–$447.00), implying upside of +23.4%.

Cencora, Inc. (COR) is a large-cap in Healthcare with 63.72B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 68/100 (BUY). Sentiment: neutral at 56/100. Price: $326.50 (in the middle of its 52-week range). The current P/E ratio stands at 39.2. The 52-week range of $271.00–$377.54 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

COR|EarningsCencora, Inc.

Earnings Summary

Cencora, Inc., formerly AmerisourceBergen Corporation, is a global pharmaceutical distribution and services company operating in the Healthcare sector, specifically within the Medical Distribution industry. The company's core operations involve sourcing and distributing a wide range of pharmaceutical products and offering value-added services to healthcare providers and manufacturers. In its most recent reported quarters, Cencora has consistently exceeded analyst expectations for earnings per share. For Q3 2025, actual EPS was $3.84 against an estimate of $3.78544, and revenue was $83.729 billion. In the preceding quarter, Q2 2025, actual EPS was $4.00 versus an estimate of $3.83746, with revenue at $80.664 billion. This indicates a pattern of both revenue and EPS growth, with EPS consistently surpassing analyst targets. Historically, Cencora has demonstrated a strong track record of beating EPS estimates, with Q1 2025 showing actual EPS of $4.42 against an estimate of $4.09563 and Q4 2024 reporting $3.73 actual EPS versus an estimate of $3.52024. This consistent outperformance suggests a robust operational execution and effective market positioning. Recent news indicates Cencora is preparing for its Q2 2026 earnings release, with analysts forecasting an increase in EPS, continuing the trend of exceeding estimates. The company also recently expanded its operations through the acquisition of EyeSouth Partners' retina business, a development investors will monitor for its impact on future performance and integration. Despite a recent pullback in share price, longer-term shareholder returns remain strong, suggesting potential undervaluation. Investors will be watching for management's commentary on the integration of the new acquisition, updated guidance for the fiscal year, and any further developments impacting its market share in the retina segment.

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$4.73	-	-
Q3'25	$3.79	$3.84	+1.4%
Q2'25	$3.84	$4.00	+4.2%
Q1'25	$4.10	$4.42	+7.9%
Q4'24	$3.52	$3.73	+6.0%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$81.0B	-	-
Q3'25	-	$83.7B	-
Q2'25	-	$80.7B	-
Q1'25	-	$75.5B	-
Q4'24	-	$81.5B	-

Technical Score (1D)

BUY

News Sentiment

BULLISH

Market Data

COR Stock Snapshot

Cencora, Inc. · Healthcare · cencora.com

News Sentiment Analysis

Sentiment gathered from recent headlines

56/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Cencora (COR), a major pharmaceutical services and drug distributor, is set to report its Q2 2026 earnings on May 6th. Analysts project an 8.8% year-over-year increase in earnings per share to $4.81, building on a trend of exceeding estimates in recent quarters. Full-year fiscal 2026 EPS is also expected to grow by 9.8%. The company recently announced an acquisition of EyeSouth Partners' retina business.

What did this article say?

Analysts have collectively assigned Cencora (COR) an average rating of 'Moderate Buy'. This consensus suggests a generally positive outlook from market observers regarding the company's prospects. The rating reflects a balance of perceived strengths and potential areas for growth.

What did this article say?

Camino Minerals Corporation (COR) has initiated drilling at its Costa de Cobre IOCG copper discovery in Peru. The company has also entered a joint venture with Nittetsu Mining, where COR will operate and hold a 65% stake. This move signals a new phase of exploration and development for the copper project.

What did this article say?

DarioHealth Corp. (COR) has appointed John R. Palumbo to its Board of Directors, signaling a strategic move to accelerate commercial scaling. Palumbo's extensive experience and relationships within the healthcare sector are expected to bolster the company's partnerships with health systems and payers. This appointment aligns with Dario's focus on realizing its full strategic value in its next growth phase.

What did this article say?

Cencora (COR) has experienced short-term share price volatility, declining approximately 8% over the past month. However, longer-term shareholder returns remain robust, with 1-year and 5-year returns of 13.66% and 183.05%, respectively. This divergence suggests a cooling of short-term momentum while the company's fundamental outlook remains positive. The current pullback may present a reasonable entry point for investors, though some valuation estimates indicate the stock may still be undervalued.

What did this article say?

Cencora (COR) has received a reaffirmed buy rating for 2025, driven by its robust fundamental strength. The company's commitment to dividend growth, coupled with a low payout ratio and an A-level credit rating, underpins this positive outlook. These factors suggest continued financial stability and potential for shareholder returns.

What did this article say?

Evercore ISI has reduced its price target for Cencora (COR) from $420 to $360. Despite this adjustment, the firm has reiterated its 'Outperform' rating on the stock. This move suggests a recalibration of near-term expectations by the analyst, though the underlying positive view on COR's prospects remains.

What did this article say?

Evercore ISI Group has reiterated an Outperform rating on Cencora (COR). However, the firm has lowered its price target for the stock from $420 to $360. This adjustment suggests a recalibration of near-term valuation expectations by the analyst.

What did this article say?

Cencora Inc. (COR) experienced underperformance relative to its peers during Monday's trading session. This divergence suggests potential headwinds or sector-specific pressures impacting COR more acutely than its competitors. Traders should monitor the specific reasons for this underperformance and any potential catalysts that could shift COR's trajectory.

What did this article say?

Cencora Inc. demonstrated robust performance, outperforming its competitors during a strong trading day. This upward movement suggests positive investor sentiment or specific company-driven factors contributing to its relative strength. Traders should monitor any ongoing catalysts that differentiate COR from its peers.

COR|EarningsCencora, Inc.

Earnings Summary

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$4.73	-	-
Q3'25	$3.79	$3.84	+1.4%
Q2'25	$3.84	$4.00	+4.2%
Q1'25	$4.10	$4.42	+7.9%
Q4'24	$3.52	$3.73	+6.0%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$81.0B	-	-
Q3'25	-	$83.7B	-
Q2'25	-	$80.7B	-
Q1'25	-	$75.5B	-
Q4'24	-	$81.5B	-

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

COR·Cencora, Inc.

COR Stock Snapshot

Earnings | EPS

Revenue

COR·Cencora, Inc.

COR Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

News Sentiment Analysis

Recent News Coverage

COR·Cencora, Inc.

COR Stock Snapshot

Earnings | EPS

Revenue

COR·Cencora, Inc.

COR Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More